Breast Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: BRS044 MIFTS: 58	Breast Adenocarcinoma Categories: Rare diseases, Reproductive diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Breast Adenocarcinoma

MalaCards integrated aliases for Breast Adenocarcinoma:

Name: Breast Adenocarcinoma ¹² ²⁸ ¹⁴ ⁶⁹

Mammary Adenocarcinoma ¹² ⁶⁹

Adenocarcinoma of Breast ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3458

NCIt ⁴⁶ C5214

UMLS ⁶⁹ C0858252 C3669246

Sources

Summaries for Breast Adenocarcinoma

Disease Ontology : ¹² A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.

MalaCards based summary : Breast Adenocarcinoma, also known as mammary adenocarcinoma, is related to adenocarcinoma and squamous cell carcinoma. An important gene associated with Breast Adenocarcinoma is RB1CC1 (RB1 Inducible Coiled-Coil 1), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Paclitaxel and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Breast Adenocarcinoma

Diseases in the Breast Adenocarcinoma family:

Rare Adenocarcinoma of the Breast

Diseases related to Breast Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	31.6	CDKN1A EGF EGFR ERBB2 TP53
2	squamous cell carcinoma	29.8	CDKN1A EGF EGFR ERBB2 MMP9 TP53
3	fibrosarcoma	29.6	CDKN1A MMP9 PLAU TNF
4	neuroblastoma	29.4	CASP8 CASP9 CYCS PARP1 TP53
5	hepatocellular carcinoma	28.6	BAX CASP8 CASP9 CDKN1A CYCS EGFR
6	prostate cancer	27.7	BAX CASP8 CASP9 CDKN1A CYCS EGF
7	colorectal cancer	27.2	BAX CASP8 CASP9 CDKN1A CYCS EGF
8	vestibular gland benign neoplasm	10.6	ESR1 TP53
9	endometrial clear cell adenocarcinoma	10.6	ESR1 TP53
10	bartholin's gland adenoma	10.6	ESR1 TP53
11	glassy cell carcinoma of the cervix	10.6	ERBB2 ESR1
12	breast intraductal proliferative lesion	10.6	EGFR ERBB2
13	adult hepatocellular carcinoma	10.6	CASP8 EGF TP53
14	brain ependymoma	10.6	EGFR TP53
15	breast benign neoplasm	10.6	ERBB2 ESR1 TP53
16	thoracic benign neoplasm	10.6	ERBB2 ESR1 TP53
17	uterine corpus cancer	10.6	ERBB2 ESR1 TP53
18	mixed cell type cancer	10.6	ERBB2 ESR1 TP53
19	fallopian tube carcinoma	10.6	ERBB2 ESR1 TP53
20	microglandular adenosis	10.6	EGFR ERBB2 TP53
21	breast scirrhous carcinoma	10.6	EGFR ERBB2 ESR1
22	suppressor of tumorigenicity 3	10.6	BAX CDKN1A TP53
23	oncocytic breast carcinoma	10.6	EGFR ERBB2 ESR1
24	sweat gland cancer	10.6	ERBB2 ESR1 TP53
25	estrogen-receptor negative breast cancer	10.6	EGF ERBB2 ESR1
26	breast adenoid cystic carcinoma	10.5	EGFR ERBB2 ESR1
27	female breast cancer	10.5	ERBB2 ESR1 TP53
28	pigmented villonodular synovitis	10.5	MMP9 TNFSF11 TP53
29	luminal breast carcinoma	10.5	EGFR ERBB2 ESR1
30	breast carcinoma in situ	10.5	ERBB2 ESR1 TP53
31	uterine carcinosarcoma	10.5	EGFR ERBB2 TP53
32	cholesteatoma of middle ear	10.5	EGF MMP9 TNFSF11
33	primary peritoneal carcinoma	10.5	EGFR ERBB2 TP53
34	inflammatory breast carcinoma	10.5	EGFR ERBB2 ESR1
35	small intestinal adenocarcinoma	10.5	BAX EGFR ERBB2
36	lipid-rich carcinoma	10.5	EGFR ERBB2 ESR1
37	keratocystic odontogenic tumor	10.5	MMP9 TNFSF11 TP53
38	endometrial adenosquamous carcinoma	10.5	EGF PLAU
39	mammary paget's disease	10.5	EGFR ERBB2 ESR1
40	cheilitis	10.5	CDKN1A MMP9 TP53
41	tubular adenocarcinoma	10.5	EGFR ERBB2 ESR1
42	sporadic breast cancer	10.5	ERBB2 ESR1 TP53
43	triple-receptor negative breast cancer	10.5	ERBB2 ESR1 PARP1
44	pharynx cancer	10.5	EGFR MMP9 TP53
45	autonomic nervous system neoplasm	10.5	CASP8 CYCS TP53
46	carbuncle	10.5	BAX CASP9 CYCS
47	actinic cheilitis	10.5	CDKN1A TNF TP53
48	intracystic papillary adenoma	10.5	EGFR ERBB2
49	tongue cancer	10.5	CDKN1A MMP9 TP53
50	soft tissue sarcoma	10.5	EGFR TNF TP53

Graphical network of the top 20 diseases related to Breast Adenocarcinoma:

Sources

Symptoms & Phenotypes for Breast Adenocarcinoma

GenomeRNAi Phenotypes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.77	TP53 BAX CASP8 CASP9 CDKN1A SLC22A18
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.77	TP53 BAX CASP8 CASP9 CDKN1A SLC22A18

MGI Mouse Phenotypes related to Breast Adenocarcinoma:

⁴³ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.54	TP53 CYCS CTSK EGFR BAX CASP9
2	growth/size/body region	MP:0005378	10.53	TP53 TNFSF11 EGF CTSK EGFR CYCS
3	hematopoietic system	MP:0005397	10.49	TP53 TNFSF11 CTSK EGFR CYCS BAX
4	immune system	MP:0005387	10.49	TP53 TNFSF11 EGF CTSK EGFR CYCS
5	endocrine/exocrine gland	MP:0005379	10.46	TP53 TNFSF11 CYCS EGF CTSK EGFR
6	homeostasis/metabolism	MP:0005376	10.45	TP53 TNFSF11 CDKN1A CTSK CASP8 BAX
7	behavior/neurological	MP:0005386	10.4	TNFSF11 TNF TP53 CYCS CDKN1A BAX
8	cardiovascular system	MP:0005385	10.4	TNF TP53 CDKN1A CYCS CASP8 CASP9
9	integument	MP:0010771	10.4	TP53 TNFSF11 EGF EGFR CDKN1A CASP8
10	mortality/aging	MP:0010768	10.38	TNF TP53 TNFSF11 CDKN1A CYCS CASP8
11	craniofacial	MP:0005382	10.35	TP53 TNFSF11 CYCS CTSK CDKN1A CASP9
12	digestive/alimentary	MP:0005381	10.34	TP53 CDKN1A EGF CTSK ERBB2 EGFR
13	embryo	MP:0005380	10.33	TNF TP53 CDKN1A CYCS CASP8 CASP9
14	nervous system	MP:0003631	10.28	TP53 CYCS CTSK CDKN1A CASP8 BAX
15	limbs/digits/tail	MP:0005371	10.25	TP53 TNFSF11 CTSK EGFR BAX CDKN1A
16	neoplasm	MP:0002006	10.25	TP53 TNFSF11 EGFR BAX CDKN1A CASP8
17	adipose tissue	MP:0005375	10.23	TNF TP53 CDKN1A CTSK ESR1 EGFR
18	muscle	MP:0005369	10.23	TP53 TNFSF11 CDKN1A CASP8 BAX ERBB2
19	liver/biliary system	MP:0005370	10.15	TNF TP53 CDKN1A CASP8 ESR1 EGFR
20	hearing/vestibular/ear	MP:0005377	10.11	TP53 CDKN1A BAX EGFR FOS PLAU
21	reproductive system	MP:0005389	10.07	TP53 TNFSF11 EGF CDKN1A BAX ERBB2
22	no phenotypic analysis	MP:0003012	9.97	TNFSF11 TNF TP53 CDKN1A EGFR ESR1
23	respiratory system	MP:0005388	9.97	TP53 TNFSF11 CTSK EGFR BAX CASP9
24	renal/urinary system	MP:0005367	9.92	TP53 CDKN1A CASP8 BAX ESR1 EGFR
25	skeleton	MP:0005390	9.77	TP53 TNFSF11 CYCS CTSK CDKN1A BAX
26	vision/eye	MP:0005391	9.36	TP53 TNFSF11 CDKN1A EGF BAX EGFR

Sources

Drugs & Therapeutics for Breast Adenocarcinoma

Drugs for Breast Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3, Phase 1

33069-62-4

36314

Letrozole

Approved, Investigational

Phase 3,Phase 2

112809-51-5

3902

Tamoxifen

Approved

Phase 3

10540-29-1

2733526

Cyclophosphamide

Approved, Investigational

Phase 3,Phase 2,Phase 1

50-18-0, 6055-19-2

2907

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Trastuzumab

Approved, Investigational

Phase 3,Phase 2

180288-69-1

9903

Carboplatin

Approved

Phase 3,Phase 1,Phase 2

41575-94-4

10339178 38904 498142

Anastrozole

Approved, Investigational

Phase 3,Phase 2

120511-73-1

2187

Exemestane

Approved, Investigational

Phase 3,Phase 2

107868-30-4

60198

Zoledronic acid

Approved

Phase 3

118072-93-8

68740

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Albumin-Bound Paclitaxel

Phase 2, Phase 3, Phase 1

Antimitotic Agents

Phase 2, Phase 3, Phase 1

Antineoplastic Agents, Phytogenic

Phase 2, Phase 3, Phase 1

Antirheumatic Agents

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Anticoagulants

Phase 3

Antineoplastic Agents, Hormonal

Phase 3,Phase 2

Aromatase Inhibitors

Phase 3,Phase 2

Bone Density Conservation Agents

Phase 3

Calcium, Dietary

Phase 3

Chelating Agents

Phase 3

Estrogen Antagonists

Phase 3,Phase 2

Estrogen Receptor Modulators

Phase 3

Estrogens

Phase 3,Phase 2,Phase 1

Hormone Antagonists

Phase 3,Phase 2

Hormones

Phase 3,Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2

Selective Estrogen Receptor Modulators

Phase 3

Steroid Synthesis Inhibitors

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Diphosphonates

Phase 3

Citrate

Nutraceutical

Phase 3

Hydroxychloroquine

Approved

Phase 2

118-42-3

3652

Lenograstim

Approved, Investigational

Phase 2,Phase 1

135968-09-1

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Sulindac

Approved, Investigational

Phase 2

38194-50-2

1548887 5352

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4, 85898-30-2

Epirubicin

Approved

Phase 2

56420-45-2

41867

Testosterone

Approved, Investigational

Phase 2

58-22-0

6013

Estradiol

Approved, Investigational, Vet_approved

Phase 2

50-28-2

5757

Fulvestrant

Approved, Investigational

Phase 2

129453-61-8

17756771 104741

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286 11431660 5005498

Azacitidine

Approved, Investigational

Phase 2

320-67-2

9444

Decitabine

Approved, Investigational

Phase 2

2353-33-5

451668

Pembrolizumab

Approved

Phase 2,Phase 1,Early Phase 1

1374853-91-4

Interventional clinical trials:

(show top 50) (show all 52)

#	Name	Status	NCT ID	Phase	Drugs
1	Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer	Completed	NCT00949598	Phase 3	letrozole;tamoxifen citrate
2	A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer	Recruiting	NCT03337724	Phase 2, Phase 3	Ipatasertib;Paclitaxel;Placebo
3	Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer	Recruiting	NCT02488967	Phase 3	Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
4	Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement	Active, not recruiting	NCT00869206	Phase 3	zoledronic acid
5	Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)	Active, not recruiting	NCT00310180	Phase 3	Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
6	Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer	Active, not recruiting	NCT00005970	Phase 3	Aromatase Inhibition Therapy;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Tamoxifen Citrate
7	Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients	Unknown status	NCT01292408	Phase 2	Hydrochloroquine
8	Study of MDX-010 in Stage IV Breast Cancer	Completed	NCT00083278	Phase 2	MDX-010
9	Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer	Completed	NCT02063893	Phase 1, Phase 2
10	Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer	Completed	NCT00039520	Phase 2	docetaxel;sulindac
11	Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer	Completed	NCT00019916	Phase 1, Phase 2
12	Chemotherapy in Treating Women With Metastatic Breast Cancer	Completed	NCT00004046	Phase 2	exatecan mesylate
13	A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer	Completed	NCT02301988	Phase 2	Ipatasertib;Paclitaxel;Placebo
14	Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes	Completed	NCT01693549	Phase 2	Cabazitaxel
15	Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer	Completed	NCT00054301	Phase 2
16	Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility	Completed	NCT00591851	Phase 2	AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
17	CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer	Recruiting	NCT02067741	Phase 2	CR1447
18	IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma	Recruiting	NCT02614833	Phase 2	Placebo;Paclitaxel
19	Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer	Recruiting	NCT01928589	Phase 1, Phase 2
20	Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant	Recruiting	NCT02894398	Phase 2	Palbociclib;Letrozole;Anastrozole;Exemestane;Fulvestrant
21	A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread	Recruiting	NCT02322814	Phase 2	Cobimetinib;Paclitaxel;Placebo;Atezolizumab;Nab-Paclitaxel
22	Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca	Recruiting	NCT02957968	Phase 2	Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
23	Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer	Recruiting	NCT01697293	Phase 1, Phase 2	Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel;Triciribine Phosphate
24	Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer	Recruiting	NCT01730833	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation
25	Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation	Recruiting	NCT01245712	Phase 2
26	Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer	Recruiting	NCT02530489	Phase 2	MPDL3280A;Nab-paclitaxel
27	Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation	Active, not recruiting	NCT02282345	Phase 2	Talazoparib
28	Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2	Active, not recruiting	NCT01593020	Phase 2	Paclitaxel;Eribulin;5-Fluorouracil;Epirubicin;Cyclophosphamide;Doxorubicin
29	Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	Suspended	NCT03106415	Phase 1, Phase 2	Binimetinib
30	Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer	Terminated	NCT00074269	Phase 2	cyclosporine;fludarabine phosphate;melphalan;methotrexate
31	Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer	Unknown status	NCT00009763	Phase 1	cyclosporine;paclitaxel
32	Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast	Completed	NCT02204046	Phase 1	BIWA 4
33	Vaccine Therapy in Treating Patients With Metastatic Breast Cancer	Completed	NCT00003761	Phase 1
34	Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer	Completed	NCT01502592	Phase 1
35	Clinical Trial of Trametes Versicolor in Women With Breast Cancer	Completed	NCT00680667	Phase 1
36	Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer	Recruiting	NCT02824575	Phase 1	Rebastinib;Paclitaxel;Eribulin Mesylate
37	Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)	Recruiting	NCT01724606	Phase 1	Sorafenib
38	Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer	Recruiting	NCT02453620	Phase 1	Entinostat
39	Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors	Recruiting	NCT03102320	Phase 1	Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
40	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer	Not yet recruiting	NCT03432741	Phase 1	Belinostat;Carfilzomib;Fludeoxyglucose F-18;Gemcitabine Hydrochloride;Romidepsin
41	Vaccine Therapy in Treating Patients With Metastatic Breast Cancer	Terminated	NCT00071942	Phase 1
42	Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas	Unknown status	NCT01942629
43	Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility	Completed	NCT00617370		epirubicin, cyclophosphamide, Paclitaxel,
44	Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer	Completed	NCT01024582
45	Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI	Recruiting	NCT02306538
46	Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer	Recruiting	NCT03137693
47	Engineering Gut Microbiome to Target Breast Cancer	Recruiting	NCT03358511
48	Older Breast Cancer Patients: Risk for Cognitive Decline	Recruiting	NCT03451383
49	Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer	Recruiting	NCT02515110
50	Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation	Recruiting	NCT03366844	Early Phase 1	Pembrolizumab

Search NIH Clinical Center for Breast Adenocarcinoma

Sources

Genetic Tests for Breast Adenocarcinoma

Genetic tests related to Breast Adenocarcinoma:

#	Genetic test	Affiliating Genes
1	Breast Adenocarcinoma ²⁸

Sources

Anatomical Context for Breast Adenocarcinoma

MalaCards organs/tissues related to Breast Adenocarcinoma:

³⁸

Breast, Brain, Bone, Prostate, Testes, Lung, Pancreas

Sources

Publications for Breast Adenocarcinoma

Articles related to Breast Adenocarcinoma:

(show top 50) (show all 315)

#	Title	Authors	Year
1	Chitosan-Cellulose Multifunctional Hydrogel Beads: Design, Characterization and Evaluation of Cytocompatibility with Breast Adenocarcinoma and Osteoblast Cells. ( 29315214 )	Trivedi P....Fardim P.	2018
2	Lycopene-rich extract from red guava (Psidium guajava L.) displays cytotoxic effect against human breast adenocarcinoma cell line MCF-7 via an apoptotic-like pathway. ( 29433206 )	dos Santos R.C....Leite J.R.S.A.	2018
3	Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. ( 29138806 )	Chang L.C....Lee K.H.	2018
4	Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro. ( 28461972 )	Balalaeva I.V....Deyev S.M.	2017
5	Vanadium(III)-l-cysteine enhances the sensitivity of murine breast adenocarcinoma cells to cyclophosphamide by promoting apoptosis and blocking angiogenesis. ( 28466788 )	Basu A....Bhattacharya S.	2017
6	Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro. ( 29179603 )	Ganassin R....Muehlmann L.A.	2017
7	Phenolics from Rubus fairholmianus induces cytotoxicity and apoptosis in human breast adenocarcinoma cells. ( 28803117 )	George B.P....Hemmaragala N.M.	2017
8	hsa-miR-1973 MicroRNA is Significantly and Differentially Expressed in MDA-MB-231 Cells of Breast Adenocarcinoma and Xenografts Derived from the Tumor. ( 28948560 )	Fomicheva K.A....Mal'tseva D.V.	2017
9	The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60]fullerene derivative in a murine orthotopic model of breast adenocarcinoma. ( 28527736 )	Lapin N.A....Corr S.J.	2017
10	Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. ( 29147603 )	Quigley D.A....Kristensen V.	2017
11	Biotransport kinetics and intratumoral biodistribution of malonodiserinolamide-derivatized [60]fullerene in a murine model of breast adenocarcinoma. ( 29180866 )	Lapin N.A....Serda R.E.	2017
12	Persian Gulf Jellyfish (Cassiopea andromeda) Venom Fractions Induce Selective Injury and Cytochrome C Release in Mitochondria Obtained from Breast Adenocarcinoma Patients ( 28240847 )	Mirshamsi M.R....Pourahmad J.	2017
13	Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells. ( 28270066 )	Almeida I.V....Vicentini V.E.	2017
14	HER2/Topoisomerase IIa co-amplified breast adenocarcinoma "mirror" cases with different Topoisomerase IIa expression patterns. ( 28534385 )	Tsiambas E....Ragos V.	2017
15	Efficient T3P(Ar) mediated synthesis, differential cytotoxicity and apoptosis induction by indolo-triazolo-thiadiazoles in human breast adenocarcinoma cells. ( 28235427 )	Kamath P.R....Rao B.S.	2017
16	Remote Development of Tumor-to-Tumor Metastasis of Breast Adenocarcinoma in a Renal Oncocytoma. ( 28551171 )	Bitner D.P....Schenkman N.S.	2017
17	Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line. ( 28092843 )	Aletaha M....Baradaran B.	2017
18	The application of the linear quadratic model to compensate the effects of prolonged fraction delivery time on a Balb/C breast adenocarcinoma tumor: An in vivo study. ( 26630280 )	Nikzad S....Amini P.	2016
19	Role of Glutathione System Redox Potential in Apoptosis Dysregulation in MCF-7 Breast Adenocarcinoma. ( 26750929 )	Shakhristova E.V....Novitskii V.V.	2016
20	Ultrastructural Assessment of 2-(acridin-9-ylmethylene)-N-phenylhydrazinecarbothioamide activity on human breast adenocarcinoma cells. ( 27668344 )	de Almeida S.M....de Carvalho JA_nior L.B.	2016
21	Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest. ( 27441372 )	Khan F....Gauthaman K.	2016
22	Anti-proliferative and apoptosis inducing potential of hydroalcoholic Achillea wilhelmsii C. Koch extract on human breast adenocarcinoma cell lines MCF-7 and MDA-Mb-468. ( 28167484 )	Galavi H.R....Ashtiani M.	2016
23	Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. ( 27338760 )	El Hag M.I....Michael C.W.	2016
24	SERS-active Au/SiO2 clouds in powder for rapid ex vivo breast adenocarcinoma diagnosis. ( 27375955 )	Cepeda-PAcrez E....de la Rosa E.	2016
25	Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells. ( 27013580 )	He L....Hua Z.C.	2016
26	Inhibitory and Cytotoxic Activities of Chrysin on Human Breast Adenocarcinoma Cells by Induction of Apoptosis. ( 27761071 )	Samarghandian S....Samini M.	2016
27	Mitochondrial thiol modification by a targeted electrophile inhibits metabolism in breast adenocarcinoma cells by inhibiting enzyme activity and protein levels. ( 26774751 )	Smith M.R....Landar A.	2016
28	Phyto-synthesis of silver nanoparticles using Alternanthera tenella leaf extract: an effective inhibitor for the migration of human breast adenocarcinoma (MCF-7) cells. ( 26801668 )	Sathishkumar P....Palvannan T.	2016
29	A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition. ( 27551492 )	Mehdad A....de Freitas S.M.	2016
30	In vitro cytotoxic effect of tyrosine kinase inhibitor sunitinib malate alone and in combination with hyperthermia on breast adenocarcinoma MCF-7 cells. ( 27569072 )	Topcul M.R....Cetin I.	2016
31	Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. ( 27495172 )	Confino H....Keisari Y.	2016
32	Cambogin exerts anti-proliferative and pro-apoptotic effects on breast adenocarcinoma through the induction of NADPH oxidase 1 and the alteration of mitochondrial morphology and dynamics. ( 27418140 )	Shen K....Xu H.	2016
33	Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468). ( 27478778 )	Mansoori B....Baradaran B.	2016
34	Correction for Upadhyay et al., Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain. ( 26884179 )		2016
35	Cytotoxicity of Manganese (III) Complex in Human Breast Adenocarcinoma Cell Line Is Mediated by the Generation of Reactive Oxygen Species Followed by Mitochondrial Damage. ( 27461214 )	Al-Anbaky Q....Ali N.	2016
36	Microbial-catalysed derivatization of anti-cancer drug exemestane and cytotoxicity of resulting metabolites against human breast adenocarcinoma cell line (MCF-7) in vitro. ( 27521799 )	Baydoun S....Choudhary M.I.	2016
37	184AA3: a xenograft model of ER+ breast adenocarcinoma. ( 26661596 )	Hines W.C....Bissell M.J.	2016
38	Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. ( 26802496 )	Alibolandi M....Hadizadeh F.	2016
39	Aldehyde dehydrogenase 3A1 promotes multi-modality resistance and alters gene expression profile in human breast adenocarcinoma MCF-7 cells. ( 27276244 )	Voulgaridou G.P....Pappa A.	2016
40	Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma. ( 27752764 )	Zavareh S....Hashemi-Moghaddam H.	2016
41	HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. ( 27245202 )	Mansoori B....Baradaran B.	2016
42	Oxidative modification induced by photodynamic therapy with PhotofrinArII and 2-methoxyestradiol in human ovarian clear carcinoma (OvBH-1) and human breast adenocarcinoma (MCF-7) cells. ( 25960212 )	Saczko J....Kulbacka J.	2015
43	Anticancer Activity of Curcumin on Human Breast Adenocarcinoma: Role of Mcl-1 Gene. ( 26413251 )	Khazaei Koohpar Z....Hashemi M.	2015
44	RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells. ( 26397146 )	Zhu J....Tang W.	2015
45	Targeting Cellular Metabolism Chemosensitizes the Doxorubicin-Resistant Human Breast Adenocarcinoma Cells. ( 26558272 )	Ma S....Shen B.	2015
46	Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPinminiSOG. ( 26483969 )	Shilova O.N....Deyev S.M.	2015
47	Evaluation of fractionated and repeated sonodynamic therapy by using dual frequency for murine model of breast adenocarcinoma. ( 26124951 )	Alamolhoda M....Mokhtari-Dizaji M.	2015
48	Enhanced cytotoxicity in triple-negative and estrogen receptora89positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel. ( 26178079 )	Koh D.W....Feng X.	2015
49	Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. ( 25983116 )	Dhumale S.S....Pathak C.	2015
50	Sonochemotherapy of breast adenocarcinoma: an experimental in vivo model. ( 26191104 )	Yousefian B....Mokhtari-Dizaji M.	2015

Sources

Genes for Breast Adenocarcinoma

Genes related to Breast Adenocarcinoma (2 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication
1	RB1CC1	RB1 Inducible Coiled-Coil 1	Protein Coding	400	Pathogenic ⁶
2	SLC22A18	Solute Carrier Family 22 Member 18	Protein Coding	400	Pathogenic ⁶
3	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	25.85	GeneCards inferred via : Publications Expressions (show sections)
4	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	23.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	TP53	Tumor Protein P53	Protein Coding	23.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	ESR1	Estrogen Receptor 1	Protein Coding	23.09	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	TNFSF11	TNF Superfamily Member 11	Protein Coding	22.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	EGF	Epidermal Growth Factor	Protein Coding	21.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	PARP1	Poly(ADP-Ribose) Polymerase 1	Protein Coding	21.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	MMP9	Matrix Metallopeptidase 9	Protein Coding	21.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	21.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	FOS	Fos Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	21.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	CYCS	Cytochrome C, Somatic	Protein Coding	21.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	CASP8	Caspase 8	Protein Coding	20.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	TNF	Tumor Necrosis Factor	Protein Coding	20.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	CASP9	Caspase 9	Protein Coding	20.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	PLAU	Plasminogen Activator, Urokinase	Protein Coding	20.83	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	CTSK	Cathepsin K	Protein Coding	20.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	NQO1	NAD(P)H Quinone Dehydrogenase 1	Protein Coding	20.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	ALDH3A1	Aldehyde Dehydrogenase 3 Family Member A1	Protein Coding	12.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	SH3KBP1	SH3 Domain Containing Kinase Binding Protein 1	Protein Coding	11.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	WISP2	WNT1 Inducible Signaling Pathway Protein 2	Protein Coding	10.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	CASP7	Caspase 7	Protein Coding	10.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	CTSD	Cathepsin D	Protein Coding	10.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	SPAM1	Sperm Adhesion Molecule 1	Protein Coding	10.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	10.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	PXN	Paxillin	Protein Coding	10.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	BCL2L1	BCL2 Like 1	Protein Coding	10.27	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Breast Adenocarcinoma

ClinVar genetic disease variations for Breast Adenocarcinoma:

⁶ (show all 11)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	TP53	NM_000546.5(TP53): c.451C> A (p.Pro151Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934874	GRCh37	Chromosome 17, 7578479: 7578479
2	TP53	NM_000546.5(TP53): c.451C> T (p.Pro151Ser)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934874	GRCh37	Chromosome 17, 7578479: 7578479
3	KRAS	NM_033360.3(KRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic/Likely pathogenic	rs112445441	GRCh37	Chromosome 12, 25398281: 25398281
4	PIK3CA	NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913279	GRCh37	Chromosome 3, 178952085: 178952085
5	PIK3CA	NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913279	GRCh37	Chromosome 3, 178952085: 178952085
6	PIK3CA	NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh37	Chromosome 3, 178936094: 178936094
7	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	GRCh37	Chromosome 3, 178936091: 178936091
8	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh37	Chromosome 14, 105246551: 105246551
9	RB1CC1	NG_015833.1: g.34008_95699del61692	deletion	Pathogenic		GRCh38	Chromosome 8, 52623768: 52685459
10	RB1CC1	NG_015833.1: g.57807_94706del36900	deletion	Pathogenic		GRCh38	Chromosome 8, 52624761: 52661660
11	SLC22A18	NM_002555.5(SLC22A18): c.864_865insNC_000011.10: g.2919738_2919848	insertion	Pathogenic

Sources

Expression for Breast Adenocarcinoma

Search GEO for disease gene expression data for Breast Adenocarcinoma.

Sources

Pathways for Breast Adenocarcinoma

Pathways related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 129)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶² Show member pathways Immune System ⁶² Neutrophil degranulation ⁶²	14.16	CASP8 CASP9 CDKN1A CTSK EGF EGFR
2	Apoptotic Pathways in Synovial Fibroblasts ⁶⁰ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁰ Cellular Apoptosis Pathway ⁶⁰ DHA Signaling ⁶⁰ eIF2 Pathway ⁶⁰ ERK5 Signaling ⁶⁰ Glioma Invasiveness ⁶⁰ Mitochondrial Apoptosis ⁶⁰ Nuclear Receptor Activation by Vitamin-A ⁶⁰ p53 Mediated Apoptosis ⁶⁰ PPAR Pathway ⁶⁰ Rac1 Pathway ⁶⁰ Rap1 Pathway ⁶⁰ Telomerase Components in Cell Signaling ⁶⁰	13.99	BAX CASP8 CASP9 CYCS EGF EGFR
3	ERK Signaling ⁶⁰ Show member pathways ILK Signaling ⁶⁰ MAPK Signaling ⁶⁰ Molecular Mechanisms of Cancer ⁶⁰ Rho Family GTPases ⁶⁰	13.91	BAX CASP8 CASP9 CDKN1A CYCS EGF
4	PEDF Induced Signaling ⁶⁰ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁰ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶⁰ Glucocorticoid Receptor Signaling ⁶⁰ IL-6 Pathway ⁶⁰ MIF Mediated Glucocorticoid Regulation ⁶⁰ MIF Regulation of Innate Immune Cells ⁶⁰ NFAT Signaling and Lymphocyte Interactions ⁶⁰ PGC1Alpha Pathway ⁶⁰ RAR-Gamma-RXR-Alpha Degradation ⁶⁰ STAT3 Pathway ⁶⁰	13.79	BAX CASP8 CASP9 CDKN1A EGF EGFR
5	Akt Signaling ⁶⁰ Show member pathways p38 Signaling ⁶⁰ Tec Kinases Signaling ⁶⁰	13.53	BAX CASP9 CDKN1A EGF EGFR ERBB2
6	Cytokine Signaling in Immune system ⁶² Show member pathways Signaling by Interleukins ⁶²	13.49	CDKN1A EGF EGFR ERBB2 FOS MMP9
7	PAK Pathway ⁶⁰ Show member pathways Antioxidant Action of Vitamin-C ⁶⁰ Epithelial Adherens Junctions ⁶⁰	13.44	BAX CASP8 CASP9 EGF EGFR ERBB2
8	Nanog in Mammalian ESC Pluripotency ⁶⁰ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁰ eNOS Signaling ⁶⁰ GSK3 Signaling ⁶⁰	13.39	CASP8 EGF EGFR ERBB2 ESR1 FOS
9	IL-2 Pathway ⁶⁰ Show member pathways ErbB Family Pathway ⁶⁰ ErbB2-ErbB3 Heterodimers ⁶⁰ ErbB4 Pathway ⁶⁰ Growth Hormone Signaling ⁶⁰ HMGB1 Pathway ⁶⁰ IL-4 Pathway ⁶⁰ LPS Stimulated MAPK Signaling ⁶⁰ PACAP Signaling ⁶⁰ PI3K Signaling in B-Lymphocyte ⁶⁰ Prolactin Signaling ⁶⁰ Thrombopoietin Pathway ⁶⁰ TREM1 Pathway ⁶⁰ UVC-Induced MAPK Signaling ⁶⁰	13.34	BAX CYCS EGF EGFR ERBB2 FOS
10	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶² Colorectal cancer ³⁶ EGFR tyrosine kinase inhibitor resistance ³⁶ Glioma ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²¹ Signaling Pathways in Glioblastoma ¹ Thyroid cancer ³⁶	13.1	BAX CASP9 CDKN1A CYCS EGF EGFR
11	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	13.09	BAX CASP8 CASP9 CDKN1A EGF EGFR
12	Development Angiotensin activation of ERK ²¹ Show member pathways Cell adhesion Integrin inside-out signaling ²¹ Development ACM2 and ACM4 activation of ERK ²¹ Development Angiotensin signaling via PYK2 ²¹ Development EDNRB signaling ²¹ Development EPO-induced MAPK pathway ²¹ Development G-Proteins mediated regulation MARK-ERK signaling ²¹ Signal transduction IP3 signaling ²¹	13	CASP8 CASP9 CYCS EGFR FOS TNF
13	TNFR1 Pathway ⁶⁰ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²¹ Apoptosis through Death Receptors ⁶⁰ Apoptotic Pathways Triggered By HIV1 ⁶⁰ DR3 Signaling ⁶⁰ Fas Signaling ⁶⁰ GITR Pathway ⁶⁰ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶² TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁰ TRAIL Pathway ⁶⁰ TWEAK Pathway ⁶⁰	13	BAX CASP8 CASP9 CYCS MMP9 PARP1
14	Influenza A ³⁶ Show member pathways Herpes simplex infection ³⁶ Measles ³⁶	12.93	CASP8 CASP9 CYCS FOS TNF TP53
15	MAPK signaling pathway ³⁶ ¹	12.9	CASP8 CASP9 EGF EGFR FOS TNF
16	Downstream signaling events of B Cell Receptor (BCR) ⁶² Show member pathways Activation of RAS in B cells ⁶² Signaling by the B Cell Receptor (BCR) ⁶²	12.86	CASP9 CDKN1A EGF EGFR ERBB2 TP53
17	Development HGF signaling pathway ²¹ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²¹ Apoptosis and survival NGF signaling pathway ²¹ Apoptosis and survival Role of CDK5 in neuronal death and survival ²¹ Development Neurotrophin family signaling ²¹ MET activates PTPN11 ⁶² MET activates STAT3 ⁶² Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.83	BAX CASP9 CYCS ERBB2 ESR1 FOS
18	Chks in Checkpoint Regulation ⁶⁰ Show member pathways DNA Repair Mechanisms ⁶⁰ Estrogen-mediated S-Phase Entry ⁶⁰ G2-M Phase Transition ⁶⁰ Parkinson's Disease Pathway ⁶⁰ SREBP Proteolysis ⁶⁰	12.79	CASP8 CDKN1A ESR1 PARP1 TP53
19	Development Endothelin-1/EDNRA signaling ²¹ Show member pathways Cytoskeleton remodeling FAK signaling ²¹ Development Endothelin-1/EDNRA transactivation of EGFR ²¹ GnRH signaling pathway ³⁶ Inflammatory mediator regulation of TRP channels ³⁶	12.79	CASP8 CASP9 CYCS EGFR FOS PARP1
20	4-1BB Pathway ⁶⁰ Show member pathways CD27 Pathway ⁶⁰ CD40 Signaling ⁶⁰ CMV and MAPK Pathways ⁶⁰ NF-KappaB Activation by EBV ⁶⁰ NF-kappaB Activation by Viruses ⁶⁰ PKR Pathway ⁶⁰ SUMO Pathway ⁶⁰ TNFR2 Pathway ⁶⁰	12.78	EGF EGFR FOS TNF TP53
21	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁶ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²¹ Apoptosis Signaling Pathways ⁶¹ Death Receptor Signaling ⁶³	12.77	BAX CASP8 CASP9 CDKN1A CTSK CYCS
22	TRAF Pathway ⁶⁰ Show member pathways 14-3-3 Induced Apoptosis ⁶⁰ TNF Superfamily Pathway ⁶⁰ Toll-Like Receptors Pathway ⁶⁰	12.75	CASP8 CASP9 CYCS FOS TNF TNFSF11
23	Development Dopamine D2 receptor transactivation of EGFR ²¹ Show member pathways Apoptosis and survival BAD phosphorylation ²¹ BAD Phosphorylation ⁶⁰ Chemotaxis CXCR4 signaling pathway ²¹ Development Alpha-2 adrenergic receptor activation of ERK ²¹	12.69	BAX CASP9 CYCS EGF EGFR
24	Immune response IL-23 signaling pathway ²¹ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁰ Development Angiopoietin - Tie2 signaling ²¹ Development PDGF signaling via STATs and NF-kB ²¹ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²¹ Rac1/Pak1/p38/MMP-2 pathway ¹	12.68	BAX CASP9 CDKN1A EGFR ERBB2 FOS
25	MicroRNAs in cancer ³⁶	12.67	CDKN1A EGFR ERBB2 MMP9 PLAU TP53
26	Relaxin signaling pathway ³⁶ Show member pathways Endocrine resistance ³⁶ Estrogen signaling pathway ³⁶ Relaxin receptors ⁶²	12.66	BAX CDKN1A EGFR ERBB2 ESR1 FOS
27	BMP Pathway ⁶⁰ Show member pathways Caspase Cascade ⁶⁰ Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels ⁶² DREAM Repression and Dynorphin Expression ⁶⁰ nNOS Signaling in Skeletal Muscle ⁶⁰ TOB in Osteoblast Signaling ⁶⁰	12.65	CASP8 CASP9 CYCS FOS PARP1 TNF
28	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁵⁷ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.63	CDKN1A EGF EGFR ERBB2 FOS TP53
29	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.62	BAX CDKN1A EGF EGFR ERBB2 ESR1
30	Prolactin Signaling Pathway ³⁶ ¹ Show member pathways Development Prolactin receptor signaling ²¹ Leptin signaling pathway ¹	12.61	BAX ERBB2 ESR1 FOS TNFSF11
31	Development EGFR signaling pathway ²¹ Show member pathways Development ERBB-family signaling ²¹ EGF Pathway ⁶⁰ EGFR Signaling Pathway ⁶³ ErbB receptor signaling network ¹	12.61	CASP8 CASP9 EGF EGFR ERBB2 FOS
32	Apoptosis Pathway ⁶⁸ Show member pathways Akt Pathway ⁶⁸ NF-kappaB Pathway ⁶⁸	12.59	BAX CASP8 CASP9 EGFR ERBB2 TP53
33	Kaposi's sarcoma-associated herpesvirus infection ³⁶ Show member pathways Hepatitis B ³⁶	12.58	BAX CASP8 CASP9 CDKN1A CYCS FOS
34	HTLV-I infection ³⁶	12.56	BAX CDKN1A FOS TNF TP53
35	Development IGF-1 receptor signaling ²¹ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²¹ Signal transduction AKT signaling ²¹	12.53	BAX CASP9 CDKN1A FOS TP53
36	Development VEGF signaling via VEGFR2 - generic cascades ²¹ Show member pathways Development VEGF signaling and activation ²¹ VEGF - VEGF R2 Signaling Pathways ⁶¹	12.49	CASP9 ESR1 FOS PLAU
37	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁶	12.49	BAX CASP8 CASP9 CDKN1A CYCS TP53
38	VEGF Pathway (Qiagen) ⁶⁰ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁰ Development VEGF-family signaling ²¹ Neurophilin interactions with VEGF and VEGFR ⁶² VEGF Family Ligands and Receptor Interactions ⁶⁰	12.46	CASP9 EGF EGFR FOS
39	IL-17 Family Signaling Pathways ⁶¹ Show member pathways IL17 signaling pathway ¹ IL-17 signaling pathway ³⁶ Interleukin-17 signaling ⁶² Mucin expression in CF via IL-6, IL-17 signaling pathways ²¹	12.43	CASP8 FOS MMP9 TNF
40	Development Ligand-independent activation of ESR1 and ESR2 ²¹ Show member pathways Transcription CREB pathway ²¹ Transcription PPAR Pathway ²¹	12.42	EGF EGFR ERBB2 ESR1
41	Viral carcinogenesis ³⁶	12.4	BAX CASP8 CDKN1A TP53
42	Toxoplasmosis ³⁶ Show member pathways Leishmaniasis ³⁶	12.4	CASP8 CASP9 CYCS FOS TNF
43	Transcriptional misregulation in cancer ³⁶	12.4	BAX CDKN1A MMP9 PLAU TP53
44	Apoptosis and survival Caspase cascade ²¹ Show member pathways Apoptosis and survival FAS signaling cascades ²¹ Breakdown of the nuclear lamina ⁶² Caspase cascade in apoptosis ¹ Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation ¹ FasL/ CD95L signaling ⁶² Influenza A virus infection ¹	12.39	BAX CASP8 CASP9 CYCS PARP1 TNF
45	p53 Signaling ⁶⁰ Show member pathways p53 Pathway ⁶³	12.39	BAX CASP8 CASP9 CDKN1A FOS TP53
46	Tuberculosis ³⁶	12.38	BAX CASP8 CASP9 CYCS TNF
47	MAPK Signaling: Mitogen Stimulation Pathway ⁶¹ Show member pathways Akt Signaling Pathway ⁶¹	12.37	BAX CASP9 CDKN1A EGFR ERBB2 TP53
48	Proteoglycans in cancer ³⁶	12.34	CDKN1A EGFR ERBB2 ESR1 MMP9 PLAU
49	Necroptosis ³⁶ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.33	BAX CASP8 PARP1 TNF
50	EGF/EGFR Signaling Pathway ¹	12.3	EGF EGFR ERBB2 FOS

Sources

GO Terms for Breast Adenocarcinoma

Cellular components related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein complex	GO:0043234	9.17	CASP8 CASP9 CDKN1A EGFR ESR1 PARP1

Biological processes related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 49)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell migration	GO:0030335	9.98	EGF EGFR MMP9 PLAU
2	aging	GO:0007568	9.97	CASP9 FOS NQO1 TP53
3	cellular response to organic cyclic compound	GO:0071407	9.87	CASP8 CASP9 TNF
4	apoptotic signaling pathway	GO:0097190	9.87	BAX CASP8 TNF
5	positive regulation of JNK cascade	GO:0046330	9.87	RB1CC1 TNF TNFSF11
6	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.85	BAX CDKN1A TP53
7	response to toxic substance	GO:0009636	9.85	BAX CDKN1A FOS NQO1
8	positive regulation of protein phosphorylation	GO:0001934	9.85	EGFR ERBB2 MMP9 RB1CC1 TNF
9	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.84	BAX CASP9 TNF
10	positive regulation of fibroblast proliferation	GO:0048146	9.83	CDKN1A EGFR ESR1
11	response to UV	GO:0009411	9.83	CASP9 CDKN1A TP53
12	cellular response to UV	GO:0034644	9.83	BAX CASP9 TP53
13	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0006919	9.83	BAX CASP8 CASP9 TNF
14	positive regulation of protein kinase B signaling	GO:0051897	9.83	EGF EGFR ERBB2 TNF TNFSF11
15	protein kinase B signaling	GO:0043491	9.81	CASP9 CDKN1A TNF
16	extrinsic apoptotic signaling pathway	GO:0097191	9.8	BAX CASP8 TNF
17	ERBB2 signaling pathway	GO:0038128	9.8	EGF EGFR ERBB2
18	response to gamma radiation	GO:0010332	9.78	BAX PARP1 TP53
19	response to antibiotic	GO:0046677	9.77	CASP8 CASP9 TP53
20	positive regulation of neuron death	GO:1901216	9.77	CASP8 FOS PARP1
21	cellular response to cadmium ion	GO:0071276	9.76	EGFR FOS MMP9
22	positive regulation of phosphorylation	GO:0042327	9.75	EGF EGFR TNFSF11
23	regulation of cell motility	GO:2000145	9.74	EGF EGFR ERBB2
24	positive regulation of release of cytochrome c from mitochondria	GO:0090200	9.73	BAX MMP9 TP53
25	positive regulation of catenin import into nucleus	GO:0035413	9.71	EGF EGFR
26	positive regulation of osteoclast differentiation	GO:0045672	9.71	FOS TNF TNFSF11
27	positive regulation of neuron apoptotic process	GO:0043525	9.71	BAX CASP9 NQO1 TP53
28	vagina development	GO:0060068	9.7	BAX ESR1
29	positive regulation of programmed cell death	GO:0043068	9.7	CDKN1A TNF
30	response to salt stress	GO:0009651	9.69	BAX TNF
31	mammary gland alveolus development	GO:0060749	9.69	EGF ESR1 TNFSF11
32	death-inducing signaling complex assembly	GO:0071550	9.68	CASP8 TNF
33	response to cobalt ion	GO:0032025	9.67	CASP8 CASP9
34	macrophage differentiation	GO:0030225	9.67	CASP8 MMP9 PARP1
35	negative regulation of ERBB signaling pathway	GO:1901185	9.65	EGF EGFR ERBB2
36	response to estradiol	GO:0032355	9.65	CASP8 CASP9 EGFR ESR1 NQO1
37	signal transduction by p53 class mediator	GO:0072331	9.64	CDKN1A TP53
38	cellular response to reactive oxygen species	GO:0034614	9.62	EGFR FOS MMP9 TP53
39	activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c	GO:0008635	9.54	BAX CASP9 CYCS
40	intrinsic apoptotic signaling pathway	GO:0097193	9.46	BAX CDKN1A CYCS TP53
41	positive regulation of MAP kinase activity	GO:0043406	9.35	EGF EGFR ERBB2 TNF TNFSF11
42	response to organic cyclic compound	GO:0014070	9.1	CASP9 CDKN1A EGFR FOS NQO1 TP53
43	positive regulation of transcription by RNA polymerase II	GO:0045944	10.22	EGFR ESR1 FOS PARP1 TNF TNFSF11
44	apoptotic process	GO:0006915	10.15	BAX CASP8 CASP9 CYCS PARP1 TP53
45	positive regulation of transcription, DNA-templated	GO:0045893	10.11	EGF EGFR ESR1 FOS TNF TP53
46	cellular response to DNA damage stimulus	GO:0006974	10.1	BAX CASP9 CDKN1A PARP1 TP53
47	negative regulation of apoptotic process	GO:0043066	10.09	CDKN1A EGFR MMP9 NQO1 RB1CC1 TP53
48	positive regulation of apoptotic process	GO:0043065	10.04	BAX CASP9 MMP9 TNF TP53
49	regulation of apoptotic process	GO:0042981	10.02	BAX CASP8 CASP9 ESR1 TP53

Molecular functions related to Breast Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ubiquitin protein ligase binding	GO:0031625	9.72	CASP8 CDKN1A EGFR SLC22A18 TP53
2	protein phosphatase binding	GO:0019903	9.65	EGFR ERBB2 TP53
3	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.61	EGF EGFR ERBB2
4	cysteine-type endopeptidase activity	GO:0004197	9.58	CASP8 CASP9 CTSK
5	protein kinase binding	GO:0019901	9.5	CASP9 CDKN1A EGFR ESR1 PARP1 RB1CC1
6	signal transducer, downstream of receptor, with protein tyrosine kinase activity	GO:0004716	9.46	EGFR ERBB2
7	tumor necrosis factor receptor binding	GO:0005164	9.43	CASP8 TNF TNFSF11
8	nitric-oxide synthase regulator activity	GO:0030235	9.37	EGFR ESR1
9	identical protein binding	GO:0042802	9.32	BAX CASP8 EGFR ERBB2 ESR1 MMP9
10	protein binding	GO:0005515	10.13	BAX CASP8 CASP9 CDKN1A CTSK CYCS

Sources

Sources for Breast Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ Genetics Home Reference

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HGMD

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ MalaCards

³⁹ MedGen

⁴⁰ MedlinePlus

⁴¹ MeSH

⁴² MESH via Orphanet

⁴³ MGI

⁴⁴ NCBI Bookshelf

⁴⁵ NCI

⁴⁶ NCIt

⁴⁷ NDF-RT

⁴⁸ NIH Clinical Center

⁴⁹ NIH Rare Diseases

⁵⁰ NINDS

⁵¹ Novoseek

⁵² Novus Biologicals

⁵³ OMIM

⁵⁴ OMIM via Orphanet

⁵⁵ Orphanet

⁵⁶ PathCards

⁵⁷ PharmGKB

⁵⁸ PubMed

⁵⁹ PubMed Health

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via HPO

⁶⁶ SNOMED-CT via Orphanet

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ UniProtKB/Swiss-Prot

⁷² Wikipedia